Advertisement
Advertisement
USNA
USANA Health Sciences Inc
17.19
USDSponsored
+0.20
+1.16%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
17.20
+0.01
+0.09%
USNA Earnings Reports
Positive Surprise Ratio
USNA beat 24 of 40 last estimates.
60%
Next Report
Date of Next Report
Apr 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
$246.18M
/$0.44
Implied change from Q4 25 (Revenue/ EPS)
+8.83%
/-26.67%
Implied change from Q1 25 (Revenue/ EPS)
-1.35%
/-39.73%
USANA Health Sciences Inc earnings per share and revenue
On Feb 17, 2026, USNA reported earnings of 0.60 USD per share (EPS) for Q4 25, beating the estimate of 0.41 USD, resulting in a 43.47% surprise. Revenue reached 226.20 million, compared to an expected 230.48 million, with a -1.86% difference. The market reacted with a -1.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of 0.44 USD, with revenue projected to reach 246.18 million USD, implying an decrease of -26.67% EPS, and increase of 8.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were USANA Health Sciences Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, USANA Health Sciences Inc reported EPS of $0.60, beating estimates by 43.47%, and revenue of $226.20M, -1.86% below expectations.
How did the market react to USANA Health Sciences Inc's Q4 2025 earnings?
The stock price moved down -1.41%, changed from $20.60 before the earnings release to $20.31 the day after.
When is USANA Health Sciences Inc expected to report next?
The next earning report is scheduled for Apr 20, 2026.
What are the forecasts for USANA Health Sciences Inc's next earnings report?
Based on 3
analysts, USANA Health Sciences Inc is expected to report EPS of $0.44 and revenue of $246.18M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement